RU93057724A - PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARATION AND METHOD OF TREATMENT - Google Patents

PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARATION AND METHOD OF TREATMENT

Info

Publication number
RU93057724A
RU93057724A RU93057724/14A RU93057724A RU93057724A RU 93057724 A RU93057724 A RU 93057724A RU 93057724/14 A RU93057724/14 A RU 93057724/14A RU 93057724 A RU93057724 A RU 93057724A RU 93057724 A RU93057724 A RU 93057724A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
preparation
treatment
dosage form
film
Prior art date
Application number
RU93057724/14A
Other languages
Russian (ru)
Other versions
RU2098093C1 (en
Inventor
Джон Филлипс Энтони
Малькольм Пэдфилд Джон
Кит Винтерборн Ян
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104890A external-priority patent/GB9104890D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of RU93057724A publication Critical patent/RU93057724A/en
Application granted granted Critical
Publication of RU2098093C1 publication Critical patent/RU2098093C1/en

Links

Claims (1)

Фармацевтическая композиция для орального введения, включающая покрытую пленкой твердую дозированную форму, содержащую 3 - [2 - (диметиламино) этил] -N-метил -1H-индол-5- метансульфонамид или его фармацевтически приемлемую соль или сольват в качестве активного ингредиента. Твердая дозированная форма, покрытая пленкой, является полезной при лечении состояний, связанных с головной болью, в частности мигрени.A pharmaceutical composition for oral administration comprising a film-coated solid dosage form containing 3 - [2 - (dimethylamino) ethyl] -N-methyl -1H-indole-5-methanesulfonamide or its pharmaceutically acceptable salt or solvate as an active ingredient. A solid film-coated dosage form is useful in treating conditions associated with a headache, in particular migraines.
RU9393057724A 1991-03-08 1992-03-02 Sumatryptan-base pharmaceutical composition RU2098093C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9104890.0 1991-03-08
GB919104890A GB9104890D0 (en) 1991-03-08 1991-03-08 Compositions
PCT/EP1992/000460 WO1992015295A1 (en) 1991-03-08 1992-03-02 Compositions containing sumatriptan

Publications (2)

Publication Number Publication Date
RU93057724A true RU93057724A (en) 1996-05-10
RU2098093C1 RU2098093C1 (en) 1997-12-10

Family

ID=42342461

Family Applications (1)

Application Number Title Priority Date Filing Date
RU9393057724A RU2098093C1 (en) 1991-03-08 1992-03-02 Sumatryptan-base pharmaceutical composition

Country Status (29)

Country Link
US (4) US5863559A (en)
EP (1) EP0503440B1 (en)
JP (1) JP2986546B2 (en)
KR (1) KR100202042B1 (en)
AT (1) ATE165973T1 (en)
AU (1) AU663303B2 (en)
BE (1) BE1005086A5 (en)
CA (1) CA2105180C (en)
CH (1) CH684242A5 (en)
CY (1) CY2011A (en)
CZ (1) CZ282352B6 (en)
DE (1) DE69225421T2 (en)
DK (1) DK0503440T3 (en)
ES (1) ES2117015T3 (en)
FR (1) FR2673538B1 (en)
GB (2) GB9104890D0 (en)
GE (1) GEP20012549B (en)
HK (1) HK19395A (en)
IE (1) IE920726A1 (en)
IL (1) IL101162A (en)
IT (1) IT1271495B (en)
MX (1) MX9200992A (en)
NL (1) NL9200423A (en)
NZ (1) NZ241873A (en)
OA (1) OA09812A (en)
RU (1) RU2098093C1 (en)
SG (1) SG169294G (en)
WO (1) WO1992015295A1 (en)
ZA (1) ZA921690B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
ES2106818T3 (en) * 1991-10-30 1997-11-16 Glaxo Group Ltd MULTILAYER COMPOSITION CONTAINING HISTAMINE OR SECOTIN ANTAGONISTS.
DE4314976C1 (en) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermal therapeutic systems for the administration of drugs, process for their production and their use
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9924717D0 (en) * 1999-10-19 1999-12-22 Glaxo Group Ltd Diagnostic
AT500063A1 (en) 1999-11-23 2005-10-15 Sandoz Ag COATED TABLETS
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
WO2004009085A2 (en) * 2002-07-19 2004-01-29 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
WO2004060355A1 (en) * 2002-12-26 2004-07-22 Pozen Inc. Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070184109A1 (en) * 2003-06-06 2007-08-09 Floyd Alison G Compositions comprising triptans and nsaids
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
ES2624585T3 (en) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (en) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. Process for preparation of sulfamide derivatives
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
JP2010522135A (en) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
CN101687788A (en) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 The indoles that replaces
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
US8618157B2 (en) * 2008-06-20 2013-12-31 Alphapharm Pty. Ltd. Pharmaceutical formulation
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8592424B2 (en) * 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP2480197B1 (en) 2009-09-25 2015-11-11 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP2019507181A (en) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170387B (en) * 1982-06-07 1987-06-03 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS, PROCEDURE TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8419575D0 (en) * 1984-08-01 1984-09-05 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions

Similar Documents

Publication Publication Date Title
RU93057724A (en) PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARATION AND METHOD OF TREATMENT
ATE165973T1 (en) DRUGS CONTAINING SUMATRIPTAN
RU93058555A (en) Quinuclidine derivatives, a method for their production, a pharmaceutical composition, a method for the treatment or prevention
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
RU93036959A (en) FREE SOLUBLE MEDICATION WITH SLOW-UP ACTION OF BIOLOGICALLY ACTIVE SUBSTANCES, ASSIGNED FOR RECEPTION INSIDE, THE METHOD OF ITS MANUFACTURE
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
RU95101385A (en) Products containing g-csf and tnf-binding protein
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
ATE55248T1 (en) DRUG COMBINATION.
IE38655L (en) Pharmaceutical compositions
TR200103144T2 (en) New compounds
RU2005135649A (en) COMBINATIONS OF PAROXETIN AND 4- (S) - (4-ACETYLPIPERAZIN-1-IL) -2- (R) - (4-fluoro-2-methylphenyl) piperidine-1-carboxylic acid [1- (R) - (3, 5-BIS-TRIFFORMETHYLPHENYL) ETHYL] METHYLAMIDE FOR THE TREATMENT OF DEPRESSION AND / OR ALARM
CA2368352A1 (en) Method for treating neurodegeneration
KR890701111A (en) Treatment of dyslipidemia in humans
IE37288B1 (en) Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children
RU2002115270A (en) Compounds and method for treating pain
GB1375806A (en)
EP0367509A3 (en) Formulations
KR927003530A (en) Use of local anesthetics in the manufacture of pharmaceutical formulations for iontophoresis
RU98109932A (en) APPLICATION OF 1- (2-NAFT-2-YLETHYL) -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETHRHYDROPYRIDINE FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF LATERAL AMYOTRAFRAZIC
RU92016559A (en) DIALCOXY-PYRIDINYLBENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING OR TREATMENT, METHOD FOR PRODUCING THEM, USE AND INTERMEDIATE COMPOUNDS
KR890001529A (en) Pharmaceutical composition
TH19872B (en) New chemical compounds Preparation of substances and their use in pharmaceutical ingredients